76.36
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$77.52
Offen:
$77.25
24-Stunden-Volumen:
2.49M
Relative Volume:
0.54
Marktkapitalisierung:
$45.81B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$4.18B
KGV:
10.91
EPS:
7
Netto-Cashflow:
$623.10M
1W Leistung:
-2.23%
1M Leistung:
+3.64%
6M Leistung:
+7.70%
1J Leistung:
-13.37%
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
EW
Edwards Lifesciences Corp
|
76.36 | 45.81B | 5.54B | 4.18B | 623.10M | 7.00 |
![]()
ABT
Abbott Laboratories
|
133.40 | 232.39B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
100.04 | 154.11B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
382.28 | 145.55B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
87.45 | 107.35B | 33.54B | 4.66B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
2025-01-30 | Hochstufung | Stifel | Hold → Buy |
2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
2024-07-25 | Herabstufung | Truist | Buy → Hold |
2024-05-30 | Eingeleitet | Goldman | Buy |
2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
2023-03-29 | Eingeleitet | UBS | Neutral |
2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-12-06 | Herabstufung | Stifel | Buy → Hold |
2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-10-26 | Eingeleitet | Mizuho | Buy |
2022-10-18 | Eingeleitet | Barclays | Overweight |
2022-10-12 | Eingeleitet | Jefferies | Buy |
2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
2022-04-13 | Eingeleitet | Truist | Buy |
2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
2022-02-02 | Hochstufung | UBS | Neutral → Buy |
2022-01-27 | Bestätigt | Citigroup | Buy |
2022-01-27 | Bestätigt | Evercore ISI | Outperform |
2022-01-27 | Bestätigt | Raymond James | Outperform |
2022-01-27 | Bestätigt | Stifel | Buy |
2022-01-27 | Bestätigt | UBS | Neutral |
2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
2021-07-30 | Bestätigt | Deutsche Bank | Hold |
2021-07-30 | Bestätigt | Jefferies | Buy |
2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
2021-07-30 | Bestätigt | Oppenheimer | Outperform |
2021-07-30 | Bestätigt | Stifel | Buy |
2021-07-30 | Bestätigt | UBS | Neutral |
2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
2021-05-25 | Eingeleitet | Barclays | Overweight |
2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2020-03-05 | Eingeleitet | Citigroup | Buy |
2020-02-13 | Eingeleitet | Goldman | Neutral |
2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
2019-07-24 | Bestätigt | BofA/Merrill | Buy |
2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
2018-11-28 | Eingeleitet | UBS | Neutral |
2018-10-16 | Eingeleitet | Barclays | Underweight |
2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Is Edwards Lifesciences Stock Underperforming the Dow? - MSN
Is Edwards Lifesciences Stock Underperforming The Dow? - Barchart.com
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
DBS Bank Adjusts Price Target on Edwards Lifesciences to $78 From $72, Maintains Hold Rating - marketscreener.com
Leerink Partnrs Has Positive Estimate for EW Q3 Earnings - Defense World
Leerink Partners Adjusts PT on Edwards Lifesciences to $83 From $77, Maintains Market Perform Rating - marketscreener.com
Health Care Slips as Sector Continues to Lag Market -- Health Care Roundup - marketscreener.com
Edwards Lifesciences stock rises following competitor’s exit - Investing.com
Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com
Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech
Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance
Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga
Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus
Edwards Lifesciences (EW) Receives Price Target Increase from Citigroup | EW Stock News - GuruFocus
Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com
Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus
Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | EW Stock News - GuruFocus
Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com
Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com
Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey
Edwards Gets FDA Approval for its Next-Generation TAVR Device - Medical Product Outsourcing
Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Rating Lowered to Hold at StockNews.com - Defense World
Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post
Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes - Cardiovascular Business
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Do Wall Street Analysts Like Edwards Lifesciences Stock? - Nasdaq
Edwards Lifesciences (EW) Sees Price Target Increase Amid Regula - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) Sees Price Target Increase by Piper Sa - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges - Investing.com
Piper Sandler Adjusts Price Target on Edwards Lifesciences to $83 From $80, Maintains Overweight Rating - marketscreener.com
Piper Sandler raises Edwards Lifesciences target to $83 - Investing.com
FDA Clears New Indication for Edwards’ Sapien 3 - Orange County Business Journal
Why Edwards Lifesciences (EW) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey
Edwards Lifesciences Corporation (EW) Announces Amendments to Employee Stock Purchase Plans - GuruFocus
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients - Yahoo Finance
Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com
Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace
FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India
FDA approves Edwards Lifesciences’ TAVR therapy - Investing.com
Edwards Lifesciences nets FDA approval opening up TAVR to patients before they show symptoms - Fierce Biotech
Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):